{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '10.1.2', 'Visit 1: Baseline / Randomization / Day 1', '62', '10.1.3 Visits 2, 3, and 4: Days 8, 15, and 22 (+/- 2 days)', '65', '10.1.4', 'Visit 5: End of treatment: Day 29 (or up to 2 days after at the latest) even in case of early', 'IMP discontinuation', '65', '10.1.5', 'Visit 6: End of study: Day 36 (+/- 2 days)', '67', '10.2', 'DEFINITION OF SOURCE DATA', '67', '10.3', 'HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT', 'DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION', '68', '10.3.1', 'Temporary treatment discontinuation with investigational medicinal product(s)', '68', '10.3.2', 'Permanent treatment discontinuation with investigational medicinal product(s)', '68', '10.3.3', 'Handling of patients after permanent treatment discontinuation', '69', '10.3.4', 'Procedure and consequence for patient withdrawal from study', '70', '10.4', 'OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING', '70', '10.4.1', 'Definitions of adverse events', '70', '10.4.1.1', 'Adverse event', '70', '10.4.1.2', 'Serious adverse event', '71', '10.4.1.3 Adverse event of special interest', '72', '10.4.2', 'Serious adverse events waived from expedited regulatory reporting to regulatory', 'authorities', '73', '10.4.3', 'General guidelines for reporting adverse events', '73', '10.4.4', 'Instructions for reporting serious adverse events', '73', '10.4.5', 'Guidelines for reporting adverse events of special interest', '74', '10.4.6', 'Guidelines for management of specific laboratory abnormalities', '74', '10.5', 'OBLIGATIONS OF THE SPONSOR', '75', '10.6', 'SAFETY INSTRUCTIONS', '76', '10.7', 'ADVERSE EVENTS MONITORING', '76', '11', 'STATISTICAL CONSIDERATIONS', '77', '11.1', 'DETERMINATION OF SAMPLE SIZE', '77', '11.2', 'DISPOSITION OF PATIENTS', '77', '11.3', 'ANALYSIS POPULATIONS', '78', '11.3.1', 'Efficacy populations', '78', '11.3.1.1', 'Modified intent-to-treat population', '78', '11.3.2', 'Safety population', '78', '11.3.3', 'Pharmacokinetic and biomarker analysis population', '78', '11.4', 'STATISTICAL METHODS', '78', 'Property of the Sanofi Group - strictly confidential', 'Page 25', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '11.4.1', 'Extent of study treatment exposure and compliance', '78', '11.4.1.1 Extent of investigational medicinal product exposure', '78', '11.4.1.2', 'Compliance', '79', '11.4.2', 'Analyses of efficacy endpoints', '79', '11.4.2.1', 'Analysis of primary efficacy endpoint', '79', '11.4.2.2 Analyses of secondary efficacy endpoints', '80', '11.4.2.3 Multiplicity considerations', '80', '11.4.3', 'Analyses of safety data', '80', '11.4.3.1', 'Adverse events', '81', '11.4.3.2', 'Laboratory data', '82', '11.4.3.3 Potential drug-induced liver injury', '82', '11.4.3.4', 'Vital signs data', '83', '11.4.3.5', 'Electrocardiogram data', '83', '11.4.4', 'Analyses of pharmacokinetic and pharmacodynamic variables', '83', '11.5', 'INTERIM ANALYSIS', '83', '12', 'ETHICAL AND REGULATORY CONSIDERATIONS', '84', '12.1', 'ETHICAL AND REGULATORY STANDARDS', '84', '12.2', 'INFORMED CONSENT', '84', '12.3', 'HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT', 'ETHICS COMMITTEE (IRB/IEC)', '84', '13', 'STUDY MONITORING', '86', '13.1', 'RESPONSIBILITIES OF THE INVESTIGATOR(S)', '86', '13.2', 'RESPONSIBILITIES OF THE SPONSOR', '86', '13.3', 'USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL', 'REQUEST', '87', '13.4', 'USE OF COMPUTERIZED SYSTEMS', '87', '14', 'ADDITIONAL REQUIREMENTS', '88', '14.1', 'CURRICULUM VITAE', '88', '14.2', 'RECORD RETENTION IN STUDY SITES', '88', '14.3', 'CONFIDENTIALITY', '88', '14.4', 'PROPERTY RIGHTS', '89', '14.5', 'DATA PROTECTION', '89', '14.6', 'INSURANCE COMPENSATION', '89', 'Property of the Sanofi Group - strictly confidential', 'Page 26', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}